AnaptysBio (NASDAQ:ANAB) Price Target Raised to $33.00

AnaptysBio (NASDAQ:ANAB) had its price target lifted by UBS Group from $23.00 to $33.00 in a research note released on Wednesday, Benzinga reports. UBS Group currently has a neutral rating on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the company. Truist Financial lifted their target price on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. HC Wainwright restated a “buy” rating and issued a $55.00 target price on shares of AnaptysBio in a report on Wednesday, August 14th. Guggenheim lifted their target price on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Monday, October 21st. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Wedbush restated an “outperform” rating and issued a $42.00 target price on shares of AnaptysBio in a report on Thursday, September 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $55.73.

AnaptysBio Stock Performance

Shares of ANAB stock opened at $21.68 on Wednesday. AnaptysBio has a 1 year low of $13.36 and a 1 year high of $41.31. The stock has a market cap of $594.77 million, a PE ratio of -3.41 and a beta of -0.29. The business’s fifty day moving average is $34.28 and its 200-day moving average is $29.88.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%. The firm had revenue of $10.97 million for the quarter, compared to analyst estimates of $25.85 million. Equities research analysts predict that AnaptysBio will post -6.84 earnings per share for the current year.

Insider Activity

In other news, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of AnaptysBio stock in a transaction that occurred on Wednesday, August 14th. The stock was purchased at an average price of $36.50 per share, with a total value of $9,999,978.00. Following the completion of the transaction, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CFO Dennis Mulroy sold 12,220 shares of AnaptysBio stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Ecor1 Capital, Llc acquired 273,972 shares of AnaptysBio stock in a transaction that occurred on Wednesday, August 14th. The shares were purchased at an average cost of $36.50 per share, with a total value of $9,999,978.00. Following the transaction, the insider now owns 7,794,996 shares of the company’s stock, valued at approximately $284,517,354. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 22,440 shares of company stock worth $892,936. 33.70% of the stock is owned by corporate insiders.

Institutional Trading of AnaptysBio

A number of institutional investors have recently bought and sold shares of the company. Ensign Peak Advisors Inc lifted its position in shares of AnaptysBio by 74.4% in the second quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company’s stock worth $1,898,000 after buying an additional 32,313 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of AnaptysBio in the first quarter worth about $420,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of AnaptysBio in the first quarter worth about $1,221,000. Assenagon Asset Management S.A. lifted its position in shares of AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after buying an additional 168,813 shares during the last quarter. Finally, Alpha DNA Investment Management LLC acquired a new stake in shares of AnaptysBio in the second quarter worth about $399,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.